Clinical Trials Browser

Phase 1 × Medulloblastoma × Methotrexate × Clear all

NCT06466798 2026-01-08

Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies

Phase 1 Withdrawn

Ependymoma, Medulloblastoma, Central Nervous System Neoplasms